Tonix Pharmaceuticals Holding (TNXP) Metrics: History & Chart

Tonix Pharmaceuticals Holding Corp.(TNXP)

Biotechnology · Berkeley Heights, NJ

$7.70-0.38 (-4.65%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.

Berkeley Heights, NJ

142 employees

www.tonixpharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Seth Lederman

View full financials

Third-Party DCF Estimate (FMP)	$24.36
Price Gap vs Third-Party Estimate	+208.70%

7D Total Return	0.00%
30D Total Return	0.00%
YTD Total Return	0.00%
1Y Total Return	-50.00%
3Y Total Return	-99.42%
5Y Total Return	-100.00%
10Y Total Return	-100.00%
15Y Total Return	N/A
20Y Total Return	N/A

2026	0.00%
2025	-66.67%
2024	-97.46%
2023	-83.45%
2022	-96.60%
2021	-47.01%
2020

CAGR TTM	-49.83%
CAGR 3Y	-82.05%
CAGR 5Y	-87.55%
CAGR 10Y	-79.42%
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

TNXP Valuation Metrics

TNXP Stock Price Metrics

TNXP Dividend Metrics

TNXP Growth Rate Metrics

TNXP Discounted Cash Flow Metrics

TNXP Returns By Period

TNXP Yearly Returns

TNXP Average Annual Returns By Period (CAGR)

TNXP Revenue Metrics

TNXP PE Ratio Metrics

TNXP PS Ratio Metrics

TNXP PB Ratio Metrics

TNXP Price to Free Cash Flow Ratio Metrics

TNXP Debt to Equity Ratio Metrics

TNXP PEG Ratio Metrics

TNXP FCF Yield

TNXP Earnings Yield

TNXP EBITDA Yield

TNXP OCF Yield

TNXP EV/EBIT Ratio Metrics

TNXP EV/EBITDA Ratio Metrics

TNXP EV/Assets Ratio Metrics

TNXP EV/Sales Ratio Metrics

TNXP Current Ratio Metrics

TNXP Quick Ratio Metrics

TNXP ROIC Metrics

TNXP Return on Assets Metrics

TNXP Return on Equity Metrics

TNXP Net Profit Margin Metrics

TNXP Gross Profit Margin Metrics

TNXP Tax Rate Metrics

PS Ratio	4.61
PS Ratio Avg TTM	11.00
PS Ratio Avg 3Y	12.84
Current VS TTM Avg	-58.08%
Current VS 3Y Avg	-64.10%
Current VS 5Y Avg	-64.10%

PB Ratio	0.60
PB Ratio Avg TTM	0.69
PB Ratio Avg 3Y	1.14
Current VS TTM Avg	-12.73%
Current VS 3Y Avg	-47.50%
Current VS 5Y Avg	-98.44%

PFCF Ratio	N/A
PFCF Ratio Avg TTM	N/A
PFCF Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Debt/Equity Ratio	0.01
Debt/Equity Ratio Avg TTM	0.00
Debt/Equity Ratio Avg 3Y	0.03
Current VS TTM Avg	+33.03%
Current VS 3Y Avg	-82.03%
Current VS 5Y Avg	+14.06%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	N/A
FCF Yield Avg TTM	N/A
FCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	0.00
Ev/Assets Ratio Avg TTM	0.14
Ev/Assets Ratio Avg 3Y	1.69
Current VS TTM Avg	-100.00%
Current VS 3Y Avg	-100.00%
Current VS 5Y Avg	-100.00%

Ev/Sales Ratio	0.04
Ev/Sales Ratio Avg TTM	1.32
Ev/Sales Ratio Avg 3Y	23.79
Current VS TTM Avg	-96.98%
Current VS 3Y Avg	-99.83%
Current VS 5Y Avg	-99.83%

Current Ratio	6.61
Current Ratio Avg TTM	7.69
Current Ratio Avg 3Y	5.41
Current VS TTM Avg	-14.05%
Current VS 3Y Avg	+22.23%
Current VS 5Y Avg	-7.03%

Quick Ratio	6.61
Quick Ratio Avg TTM	7.51
Quick Ratio Avg 3Y	4.96
Current VS TTM Avg	-11.98%
Current VS 3Y Avg	+33.29%
Current VS 5Y Avg	-3.05%

ROIC	(74.08%)
ROIC Avg 3Y	(70.29%)
ROIC Avg 5Y	(61.17%)
Current VS 3Y Avg	-5.39%
Current VS 5Y Avg	-21.10%
Current VS 10Y Avg	+17.54%

ROA	(62.84%)
ROA Avg TTM	(15.25%)
ROA Avg 3Y	(15.01%)
Current VS TTM Avg	-312.13%
Current VS 3Y Avg	-318.79%
Current VS 5Y Avg	-352.08%

ROE	(71.83%)
ROE Avg TTM	(55.74%)
ROE Avg 3Y	(75.80%)
Current VS TTM Avg	-28.87%
Current VS 3Y Avg	+5.23%
Current VS 5Y Avg	-12.63%

Net Profit Margin	(548.64%)
Net Profit Margin Avg TTM	(828.41%)
Net Profit Margin Avg 3Y	(680.60%)
Current VS TTM Avg	+33.77%
Current VS 3Y Avg	+19.39%
Current VS 5Y Avg	-33.47%

Gross Profit Margin	34.65%
Gross Pft Margin Avg TTM	45.96%
Gross Pft Margin Avg 3Y	31.47%
Current VS TTM Avg	-24.61%
Current VS 3Y Avg	+10.11%
Current VS 5Y Avg	+77.87%

Tax Rate	0.00%
Tax Rate Avg 3Y	0.00%
Tax Rate Avg 5Y	0.00%
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	-100.00%